B
188 Pharmaceuticals
HECHO ESENCIAL
CFR PHARMACEUTICALS S.A.
Inscripción en el Registro de Valores N* 1067
Santiago, 21 de noviembre de 2012
Señor
Fernando Coloma Correa
Superintendente de Valores y Seguros
Superintendencia de Valores y Seguros
Presente
De mi consideración:
Por medio de la presente, en representación de CFR Pharmaceuticals S.A, y en cumplimiento a lo
dispuesto en el artículo 9 e inciso segundo del artículo 10, ambos de la Ley N” 18.045, en relación con
la Norma de Carácter General N” 30 de la Superintendencia de Valores y Seguros, y encontrándome
debidamente facultado por el Directorio al efecto, informo a esa Superintendencia en carácter de hecho
esencial, lo siguiente:
El día de hoy CFR Pharmaceuticals S.A. (en adelante también CFR), a través de su filial CFR
International S.p.A,, sujeto a que las condiciones de mercado lo permitan, comenzará el proceso de
colocación internacional de bonos de su propia emisión, conforme a las disposiciones de la Norma
144/A y de la Regulación S de la Securities and Exchange Comission de los Estados Unidos de
América, la que no será registrada en Chile.
De procederse con esta colocación, el monto neto final recaudado de la misma, se destinaría, de
cumplirse un conjunto de condiciones suspensivas, las que aún se encuentran pendientes, a la
adquisición del 100,00% de la participación social de las empresas colombianas denominadas
Laboratorio Franco Colombiano Lafrancol S.A.S. y Lafrancol Internacional S.A.S. (ambos conjuntamente
denominados Lafrancol), así como de los demás activos que forman parte de sus operaciones, tal como
fue informado a través de Hecho Esencial de fecha 10 de agosto de 2012.
Asimismo, aprovechamos de incluir información consolidada proforma de Lafrancol con CFR al 30 de
septiembre de 2012, no auditada, que contiene ajustes por una vez de GAAP colombiano a IFRS, que
considera la deuda al inicio, y constituye, por lo tanto, un ejercicio teórico, que forma parte de la
información que se dará a conocer a los potenciales inversionistas en los bonos referidos.
Sin otro particular, saluda atentamente a Ud.
CFR Pharmaceuticals S.A.
A
18 Pharmaceutic
Brinc
als
19 new science to life
CC: Bolsa de Comercio de Santiago
Bolsa Electrónica de Chile
Bolsa de Corredores de Valparaíso
Feller Rate Clasificadora de Riesgo Ltda.
Fitch Chile Clasificadora de Riesgo Ltda.
Representante de los Tenedores de Bonos (Banco Santander-Chile)
Adj: lo indicado
TN
UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION
The following unaudited pro forma combined financial information is based on our historical financial
statements and those of Lafrancol. The unaudited pro forma combined statement of financial position as of
September 30, 2012 combines Lafrancol’s and our historical statements of financial position as if the proposed
acquisition and the related financing had been consummated on September 30, 2012. The unaudited pro forma
combined statements of comprehensive income for the nine months ended September 30, 2012 combine Lafrancols
and our historical statements of comprehensive income as if the proposed acquisition and the related financing had
been consummated on January 1, 2011.
In preparing the unaudited pro forma financial information below, we have (1) translated the historical financial
information of Lafrancol from amounts in Colombian pesos into U.S. dollar amounts, and (2) converted the historical
financial information of Lafrancol, originally prepared under Colombian GAAP, based on the accounting policies of
the Company, which prepares its financial statements in accordance with IFRS. In addition, the unaudited pro forma
financial information below has been based on available information and certain assumptions that we believe are
reasonable in the circumstances, including, without límitation, assumptions as to the type, amount and terms of the
acquisition financing to be obtained by us, as well as the estimated amount of fees and expenses incurred in
connection with the acquisition financing. The type, amount and terms of the acquisition financing actually obtained
may differ materially from these assumptions. This unaudited pro forma financial information is presented for
informational purposes only and is not intended to represent or be indicative of the consolidated results of operations
or financial position that would have been reported had the acquisition of Lafrancol been consummated as of the
dates presented, and should not be taken as representative of our future consolidated results of operations or financial
condition.
The unaudited pro forma combined financial information includes adjustments, which are based upon
preliminaty estímates, to reflect the fair values of acquired assets and assumed liabilities of Lafrancol. Accordingly, the
pro forma adjustments to effect the determination of fair value have been made solely for the purpose of providing pro
Jerma financial information based upon current estimates and available information, and ate subject to revision based
on a final determination of fait value, which may use different methodologies and assumptions. The final fair value
will be based upon actual net tangible and intangible assets acquired as well as liabilities assumed, and actual direct
acquisition costs. Any change in the fair value of the net assets of Lafrancol will change the amount of goodwill, as
goodwill represents the difference between the consideration and the fair values of identifiable net assets acquired.
Einal accounting adjustments may differ materially from the pro forma adjustments presented here.
The historical financial information has been adjusted to give effect to events that are directly attributable to
the acquisition of Laftancol, factually supportable and, with respect to the statements of comprehensive income,
expected to have a continuing impact on the results of the combined company.
UNAUDITED PRO FORMA COMBINED STATEMENT OF FINANCIAL POSITION
As of September 30, 2012
Unaudited, including adjustment from Colombian GAAP to PERS
ASSETS:
Current assets:
Cash 8: cash equivalen
Othcr current financial as:
Other current non-fimancial asscts ….
Trade debtors $: other accounts receivable, curren
Accounts receivable from related entities, current…
Inventori
Current assets, tot:
Non-current assets:
Other non-current financial assets
Other non-current non-financial a:
Collection rights, non-current…..
Accounts receivable from related entities, non-current.
Investments booked using equity method
Intangible assets other than goodwill
Goodwil!….
Property, plant $e equipmen
Deferred tax assets …
Non-current assets, total.
Assets, total ……
EQUITY 8: LIABILITIES:
Current liabilities:
Other financial labilities, current…
Trade creditors 8e other accounts payable, current.
Accounts payable to related entitics, current…
Other provisions, current.
Current tax liabilities .
Provisions for employee benefits, current
Other non-financial liabilities, current
Current Kabilities, total..
Non- current liabilities:
Other financial liabilities, non-current ……
Other accounts payable, non-current …..
Accounts payable to related entitics, non-current
Other provisions, non-current
Deferred tax liabilities
Provisions for employee bene!
Other non-financial habilitics, non-curreni
Non-current liabilities, total…
, NON-CUTENE.
Equity:
Issued capital
Accumulated earnings (losses)
Other reserves
Equity attributable to owners of the compan:;
Non-controlling interests
Total Equity …..
Total Equity 8c Liabilities
Company 8: Lafrancol Combined (IERS; Pro Forma)
US$167,345
542
3,173
212,367
6,970
156,603
33,483
581,083
2,532
1,945
1,426
10
54,557
164,939
408,403
207,459
25,058
866,329
1,447,412
50,543
105,113
15,390
5,141
20,132
: 12,079
2,562
210,960
472,868
3
1,085
45,366
7,306
1,666
528,294
525,294
209,562
(38,034)
696,822
11,336
708,158
US$1,447,412
UNAUDITED PRO FORMA COMBINED STATEMENTS OF COMPREHENSIVE INCOME
Nine Months Ended September 30, 2012
Unaudited, including adjustment from Colombian GAAP to TERS
Company 8 Lafrancol Combined (IERS; Pro Forma)
Net sales.
US$555,430
(166,483)
Selling, general and
administrative expens
Distribution expenses
Other income (losses)
Financial income
Financial costs
Interest in results
associates and joínt
ventures..
Exchange rate differences
Adjustment unit results
388,947
(297,367)
(15,043)
2,119
2,416
(27,183)
1,505
(2,044)
250
Income before income taxes …..
53,600
Income taxes
(1,020)
Net income.
Tarnings (loss) attributable t
Owners of the company
Non-controlling intere:
52,580
54,719
(2,139)
Net income
US$52,580
Link al archivo en CMFChile: https://www.cmfchile.cl/sitio/aplic/serdoc/ver_sgd.php?s567=5d5e438a34c33e25dcb9b0758bd3fddeVFdwQmVFMXFSWGhOUkVVd1QxUmpkMDFSUFQwPQ==&secuencia=-1&t=1682366909
